A drug target for treating diseases related to skin atrophy

Abstract

The invention provides a method for treating atrophoderma related diseases by adopting application of an E-Cadherin inhibitor. , wherein the atrophoderma related diseases include but not limited to atrophoderma under physiological conditions, such as aging wrinkles, atrophodermatosis induced by mechanical strain, such as striae gravidarum and striae distensae and the like, and atrophoderma caused by taking drugs and other atrophoderma related diseases such as systemic sclerosis, dermatomyositis, ehlers-danlos syndrome, poikiloderma, Ccokayne syndrome and the like. The method has the advantages as follows: E-Cadherin is intervened to regulate and control dedifferentiation of epidermis cells, so that the stem cells are increased, and the tissue regeneration capacity is regulated; according to an example application, a siRNA inhibitor is used for silencing the E-Cadherin, the skin regeneration is obviously improved, the neogenesis of new collagen is activated, the skin thickness is increased, and the atrophoderma symptoms are alleviated.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a drug target for treating diseases related to skin atrophy. Background technique [0002] Atrophic skin disease (Atrophic Skin Disease) is a physiological or pathological degeneration of skin tissue caused by various factors. The basic pathological changes are manifested as a decrease in the number of stem cells in the basal layer, atrophy of the spiny cell layer, thinning of the epidermis, and mutation of the epidermis. flat. The ability to synthesize and secrete collagen in the dermis decreases, and the collagen fibers break and age, leading to symptoms such as dermal atrophy, thinning of the total skin thickness, and a series of diseases accompanied by skin dysfunction. Skin atrophy covers a wide range of people and has complicated causes, which is one of the problems that the academic circles urgently need to solve. However, there is no unified symptomatic treatment plan at pr...

AI Technical Summary

Problems solved by technology

Therefore, autologous stem cells are a rather limited and valuable autologous regeneration resource, which cannot sustain diseases with a long treatment cycle

[0007] (2) The process is cumbersome: at present, bone marrow mesenchymal stem cells are most used in clinical stem cell therapy. It is necessary to take drugs in advance to mobilize bone marrow mesenchymal stem cells, and then perform bone marrow puncture under local anesthesia. The operation process is cumbersome

[0008] (3) In vitro contamination: Stem cell treatment involves multiple procedures, and stem cells are easily contaminated by pathogens in in vitro procedures, causing safety problems

[0009] (4) Tumorigenicity: In the process of proliferation and differentiation of stem cells, genome instability leads to spontaneous mutation, and chromosomal abnormalities are prone to form tumors, posing safety hazards

[0011] 2. Defects of Sodium Hyaluronate Injection

[0013] (2) Invasive: it can only reach the dermis through the injection route, and the injection site is prone to congestion, hematoma and other post-injection complications

[0014] (3) Risk of blood vessel blockage: As it is a dermal injection, if the operator is inexperienced or improperly operated, serious complications may occur, such as the injection blocks local blood vessels, causing local skin tissue necrosis, and even blindness in severe cases

[0015] 3. Defects of collagen injection

[0018] (3) Invasive: it can only reach the dermis through the injection route, and the injection site is prone to congestion, hematoma and other post-injection complications

[0019] 4. Defects of Botulinum Toxin Injection

[0021] (2) Adverse reactions: adverse reactions after botulinum toxin injection include headache, back pain, etc.

[0022] (3) Invasive: the effect can only be achieved through injection, and post-injection complications such as congestion and bruising are prone to occur at the injection site

[0023] (4) Only anti-wrinkle effect: the target of botulinum toxin is neurotransmitter, which achieves anti-wrinkle effect by paralyzing nerves, but does not directly affect the dermal interstitium, does not increase the content of collagen and intercellular matrix, and also Can not really promote the regeneration of skin tissue

However, there is no report on a drug target for the treatment of skin atrophy-related diseases

Images